Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children

Documenti analoghi

• Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing
  di: Amy J. Turner, et al.
  Pubblicazione: (2024)
• The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239
  di: Christine Huynh, et al.
  Pubblicazione: (2024)
• First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
  di: Hidetoshi Shimizu, et al.
  Pubblicazione: (2024)
• Impact of CYP2D6 Genotype and Inhibitor Use on Risperidone Metabolism in Children: Functional Insights Into the *17 and *29 Alleles
  di: Matthew H. Bennett, et al.
  Pubblicazione: (2026)
• Correction to “Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects”
  Pubblicazione: (2024)